PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Internal Medicine10.3904/kjim.2014.29.6.7852014296785Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapyHo Cheol Shin, Jongwon Seo, Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Yoo Jin Lee, Seoae Han, Sang Kyung Seo, Jong Gwang Kim, Sang Kyun Sohn, Tae-In Parkhttp://synapse.koreamed.org/pdf/10.3904/kjim.2014.29.6.785, http://synapse.koreamed.org/DOIx.php?id=10.3904/kjim.2014.29.6.785, http://www.kjim.org/upload/kjim-29-6-12_785-792.pdf
Clinical Lymphoma Myeloma and Leukemia10.1016/j.clml.2013.09.009201414137-42Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative TherapyLawrence D. Kaplan, Steven R. Deitcher, Jeffrey A. Silverman, Gareth Morganhttps://api.elsevier.com/content/article/PII:S2152265013004308?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2152265013004308?httpAccept=text/plain
Clinical Lymphoma Myeloma and Leukemia10.1016/j.clml.2011.04.0052011115379-384Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of LiteratureAjay Nooka, Pareen J. Shenoy, Rajni Sinha, Sagar Lonial, Christopher R. Flowershttps://api.elsevier.com/content/article/PII:S2152265011000541?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2152265011000541?httpAccept=text/plain
Clinical Lymphoma10.1016/s1526-9655(11)70168-3200114257-258Rituximab Plus CHOP is Superior to CHOP Alone for Aggressive Diffuse Large B-Cell Lymphoma: Interim Results of a GELA Phase III TrialAmy I. D'Oraziohttps://api.elsevier.com/content/article/PII:S1526965511701683?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511701683?httpAccept=text/plain
Clinical Lymphoma10.3816/clm.2001.n.021200123155-163Diffuse Large-Cell Lymphomas: A Review of TherapyJohn E. Godwin, Richard I. Fisherhttps://api.elsevier.com/content/article/PII:S1526965511701476?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511701476?httpAccept=text/plain
Clinical Lymphoma and Myeloma10.3816/clm.2009.n.093200996E31Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without RituximabHarshal Nandurkar, Kritika Chaiwatanatorn, Georgia Stamaratis, Kenneth Opeskin, Frank Firkinhttps://api.elsevier.com/content/article/PII:S1557919011700440?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1557919011700440?httpAccept=text/plain
Clinical Lymphoma10.1016/s1526-9655(11)70190-720001127-28Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma1https://api.elsevier.com/content/article/PII:S1526965511701907?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511701907?httpAccept=text/plain
Hematological Oncology10.1002/hon.24_2631201937361-362THE SIGNIFICANCE OF PD-L1 AND PD1 RECEPTORS EXPRESSION IN PATIENTS WITH DIFFUSE B-CELL LARGE-CELL LYMPHOMAS. Samarina, A. Luchinin, N. Minaeva, N. Semenova, S. Gritsaevhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhon.24_2631, http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.24_2631/fullpdf
Clinical Lymphoma Myeloma and Leukemia10.1016/j.clml.2015.07.151201515S74The clinical significance of cereblon expression, as an effective therapeutic target, in patients with diffuse large B-cell lymphomaZijun Y. Xu-Monette, Ruifang Sun, Yi Xia, Xiaoxiao Wang, Xin Li, Ken H. Younghttps://api.elsevier.com/content/article/PII:S2152265015005674?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2152265015005674?httpAccept=text/plain
Acta Histochemica10.1016/j.acthis.2013.06.00320141161126-130Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphomaSong Lin, Li YuJun, Xing XiaoMing, Ran WenWenhttps://api.elsevier.com/content/article/PII:S0065128113001153?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0065128113001153?httpAccept=text/plain